BridgeBio Pharma (BBIO) Price & Analysis

Compare

1,385 Followers

BBIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.72 - $52.85

Previous CloseN/A

Volume379.31K

Average Volume (3M)2.69M

Market Cap

$9.89B

Enterprise Value$10.16B

Total Cash (Recent Filing)$757.34M

Total Debt (Recent Filing)$2.68B

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Oct 30, 2025

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.95

Shares Outstanding191,168,500

10 Day Avg. Volume2,233,909

30 Day Avg. Volume2,689,995

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.03

Enterprise Value/Revenue43.07

Enterprise Value/Gross Profit44.49

Enterprise Value/Ebitda-15.78

Forecast

1Y Price Target

$63.29

Price Target Upside26.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering19

Bulls Say, Bears Say

Bulls Say

Financial OutlookWith cash on hand, growing top-line, and flattening or declining expenses, the company is well-positioned financially.

Market PerformanceATTRUBY™ (acoramidis) sales in the U.S. continue to beat expectations, showing strong market performance.

Pipeline ReadoutsBridgeBio is added to the Positive Catalyst Watch List ahead of key pivotal readouts for the pipeline.

Bears Say

Market CompetitionThe ATTR-CM market is large enough to support multiple modality winners, with Attruby expected to become the market share leader in the coming years.

BridgeBio Pharma News

3 Best Stocks to Buy Now, 9/3/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

19h ago

BBIO

VNOM

JPMorgan ups BridgeBio target, adds ‘Positive Catalyst Watch’

JPMorgan analyst Anupam Rama raised the firm’s price target on BridgeBio (BBIO) to $70 from $55 and keeps...

1d ago

BBIO

3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2d ago

BBIO

MLYS

BridgeBio presents data from ATTRibute-CM open label extension through month 42

BridgeBio (BBIO) Pharma presented data from the ATTRibute-CM open label extension through Month 42, which demonstrated a statistically...

3d ago

BBIO

BridgeBio price target raised to $70 from $56 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $70 from $56 and...

6d ago

BBIO

BridgeBio price target raised to $57 from $55 at Scotiabank

Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $57 from $55 and keeps an Outperform rating...

29d ago

BBIO

BridgeBio price target raised to $61 from $60 at Oppenheimer

Oppenheimer raised the firm’s price target on BridgeBio (BBIO) to $61 from $60 and keeps an Outperform rating...

29d ago

BBIO

Closing Bell Movers: Snap down 17%, Super Micro down 16% on earnings

In the opening hour of the evening session, U.S. equity futures are on the back foot, with S&P...

30d ago

AMD

LRN

BridgeBio reports Q2 EPS (95c), consensus (61c)

Reports Q2 revenue $110.57M, consensus $88.78M. The $108.4M increase in total revenues, net was due to a $71.5M...

30d ago

BBIO

BridgeBio Pharma: Promising Pipeline and Market Position Drive Buy Rating

Anupam Rama, an analyst from J.P. Morgan, maintained the Buy rating on BridgeBio Pharma. The associated price target...

1d ago

BBIO

BridgeBio Pharma: Promising Phase 3 Data and Strong Financial Performance Justify Buy Rating

Analyst David Lebowitz of Citi maintained a Buy rating on BridgeBio Pharma, retaining the price target of $67.00....

2d ago

BBIO

BridgeBio Pharma’s Earnings Call Highlights Strong Growth

Bridgebio Pharma (($BBIO)) has held its Q2 earnings call. Read on for the main highlights of the call....

22d ago

BBIO

BridgeBio Pharma Reports Strong Q2 2025 Results

Bridgebio Pharma ( ($BBIO) ) has released its Q2 earnings. Here is a breakdown of the information Bridgebio...

29d ago

BBIO

Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

ALB

BBIO FAQ

What was BridgeBio Pharma Inc’s price range in the past 12 months?

BridgeBio Pharma Inc lowest stock price was $21.72 and its highest was $52.84 in the past 12 months.

What is BridgeBio Pharma Inc’s market cap?

BridgeBio Pharma Inc’s market cap is $9.89B.

When is BridgeBio Pharma Inc’s upcoming earnings report date?

BridgeBio Pharma Inc’s upcoming earnings report date is Oct 30, 2025 which is in 56 days.

How were BridgeBio Pharma Inc’s earnings last quarter?

BridgeBio Pharma Inc released its earnings results on Aug 05, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.793 by -$0.157.

Is BridgeBio Pharma Inc overvalued?

According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BridgeBio Pharma Inc pay dividends?

BridgeBio Pharma Inc does not currently pay dividends.

What is BridgeBio Pharma Inc’s EPS estimate?

BridgeBio Pharma Inc’s EPS estimate is -0.84.

How many shares outstanding does BridgeBio Pharma Inc have?

BridgeBio Pharma Inc has 191,168,500 shares outstanding.

What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?

BridgeBio Pharma Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.793. Following the earnings report the stock price went down -8.941%.

Which hedge fund is a major shareholder of BridgeBio Pharma Inc?

Currently, no hedge funds are holding shares in BBIO

BridgeBio Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

35.68%

Trailing 12-Months

Asset Growth

35.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) is a biotechnology company focused on developing innovative therapeutics for genetic diseases and cancers. The company operates primarily in the pharmaceutical sector, leveraging advanced genetic insights to identify and develop targeted therapies. BridgeBio specializes in creating treatments that address the underlying genetic causes of diseases, with a robust pipeline of product candidates across various stages of clinical development.

BridgeBio Pharma (BBIO) Earnings & Revenues

Historic Earnings Reports

BBIO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call indicated a strong performance in the launch and growth of Attruby, with significant advancements in the pipeline and financial growth. However, increased operating costs and competitive pressures were noted as challenges.View all BBIO earnings summaries

BBIO Stock 12 Month Forecast

Average Price Target

$63.29

▲(26.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","50":"$50","77":"$77","36.5":"$36.5","63.5":"$63.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,36.5,50,63.5,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50,52,54,56,58,60,62,64,66,68,70,72,74,{"y":76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50,51.02230769230769,52.04461538461538,53.066923076923075,54.08923076923077,55.11153846153846,56.13384615384615,57.15615384615384,58.178461538461534,59.200769230769225,60.22307692307692,61.245384615384616,62.26769230769231,{"y":63.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50,49.38461538461539,48.76923076923077,48.15384615384615,47.53846153846154,46.92307692307692,46.30769230769231,45.69230769230769,45.07692307692308,44.46153846153846,43.84615384615385,43.230769230769226,42.61538461538461,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >